Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Operating Leases: 2019-2025

Historic Operating Leases for Agios Pharmaceuticals (AGIO) over the last 7 years, with Sep 2025 value amounting to $44.5 million.

  • Agios Pharmaceuticals' Operating Leases fell 26.83% to $44.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.5 million, marking a year-over-year decrease of 26.83%. This contributed to the annual value of $40.2 million for FY2024, which is 29.45% down from last year.
  • Agios Pharmaceuticals' Operating Leases amounted to $44.5 million in Q3 2025, which was down 8.71% from $48.8 million recorded in Q2 2025.
  • Agios Pharmaceuticals' 5-year Operating Leases high stood at $103.0 million for Q1 2021, and its period low was $40.2 million during Q4 2024.
  • For the 3-year period, Agios Pharmaceuticals' Operating Leases averaged around $61.3 million, with its median value being $60.8 million (2024).
  • Data for Agios Pharmaceuticals' Operating Leases shows a maximum YoY declined of 29.45% (in 2024) over the last 5 years.
  • Agios Pharmaceuticals' Operating Leases (Quarterly) stood at $85.7 million in 2021, then decreased by 15.95% to $72.0 million in 2022, then declined by 20.85% to $57.0 million in 2023, then decreased by 29.45% to $40.2 million in 2024, then fell by 26.83% to $44.5 million in 2025.
  • Its last three reported values are $44.5 million in Q3 2025, $48.8 million for Q2 2025, and $52.9 million during Q1 2025.